As such, phase I/II clinical trials of drugs (bicalutamide, enzalutamide, abiraterone) that repress androgen-mediated AR-signalling pathway have begun for treating this type of breast cancer and other advanced metastatic breast cancers (see clinicaltrials.gov: NCT00468715, NCT01597193, and NCT00755885). Here, AR is linked to breast cancer.